Cargando…

Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer

BACKGROUND: Triple negative breast cancer (TNBC) is an aggressive and heterogeneous disease. Nomograms predicting outcomes of TNBC are needed for risk management. METHODS: Nomograms were based on an analysis of 296 non-metastatic TNBC patients treated at Sun Yat-sen Memorial Hospital from 2002 to 20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yaping, Wang, Ying, Deng, Heran, Tan, Cui, Li, Qian, He, Zhanghai, Wei, Wei, Zhou, Enxiang, Liu, Qiang, Liu, Jieqiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555047/ https://www.ncbi.nlm.nih.gov/pubmed/31170946 http://dx.doi.org/10.1186/s12885-019-5703-4

Ejemplares similares

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
por: Wu, Wei, et al.
Publicado: (2021)

Effect of (1)H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients
por: Tian, Zhenluan, et al.
Publicado: (2023)

Nomogram for predicting overall survival in Chinese triple-negative breast cancer patients after surgery
por: Lin, Wei-Xun, et al.
Publicado: (2022)

Construction and Validation of Nomograms Predicting Survival in Triple-Negative Breast Cancer Patients of Childbearing Age
por: Cui, Xiang, et al.
Publicado: (2021)

A nomogram prediction for the survival of patients with triple negative breast cancer
por: Lin, Yuxiang, et al.
Publicado: (2018)

Development and Validation of Nomograms for Predicting the Prognosis of Triple-Negative Breast Cancer Patients Based on 379 Chinese Patients
por: Shi, Hao, et al.
Publicado: (2019)

Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer
por: Chen, Mao-Shan, et al.
Publicado: (2022)

Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer
por: Guo, Lin-Wei, et al.
Publicado: (2018)

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial
por: Wu, Wei, et al.
Publicado: (2017)

Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status
por: Mao, Kai, et al.
Publicado: (2017)

Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma
por: Jing, Na, et al.
Publicado: (2020)

Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer
por: Cui, Xiang, et al.
Publicado: (2020)

Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome
por: Wang, Peipei, et al.
Publicado: (2020)

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Xia, Bingqing, et al.
Publicado: (2021)

Diagnostic and Prognostic Nomograms for Lung Metastasis in Triple-Negative Breast Cancer
por: Wang, Jianguo, et al.
Publicado: (2022)

A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Zhu, Meizhen, et al.
Publicado: (2021)

Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc
por: Cui, Jianxiu, et al.
Publicado: (2019)

Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics
por: Sheng, Dan-li, et al.
Publicado: (2022)

Development and validation of a nomogram in survival prediction among advanced breast cancer patients
por: Zhao, Jianli, et al.
Publicado: (2020)

Establishment and verification of a nomogram for predicting survival in patients with triple-positive breast cancer
por: Wang, Xingguang, et al.
Publicado: (2022)

Development and Validation of a Nomogram for Predicting Overall Survival in Pancreatic NeuroendocrineTumors()()
por: Miao, Dong-liu, et al.
Publicado: (2018)

A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer
por: Meng, Xiangdi, et al.
Publicado: (2023)

Impact of Atypical Hyperplasia at Surgical Margins on breast cancer outcomes in patients treated with neoadjuvant chemotherapy
por: Su, An, et al.
Publicado: (2023)

Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer
por: Duan, Fangfang, et al.
Publicado: (2021)

Development and validation of nomogram to predict risk of survival in patients with laryngeal squamous cell carcinoma
por: Cui, Jie, et al.
Publicado: (2020)

Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis
por: Xu, Yinggang, et al.
Publicado: (2022)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022)

Development and Validation of a Prognostic Nomogram for Postoperative Recurrence-Free Survival of Ameloblastoma
por: Yang, Yao-Cheng, et al.
Publicado: (2021)

The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival
por: Sun, Qian, et al.
Publicado: (2022)

SPHK1 regulates proliferation and survival responses in triple-negative breast cancer
por: Datta, Arpita, et al.
Publicado: (2014)

Development and validation of a radiomics nomogram for diagnosis of malignant pleural effusion
por: Wei, Mingzhu, et al.
Publicado: (2023)

Survival Study of Triple-Negative and Non–Triple-Negative Breast Cancer in a Brazilian Cohort
por: Gonçalves, Homero, et al.
Publicado: (2018)

Development and Validation of a Nomogram for Predicting Survival in Male Patients With Breast Cancer
por: Chen, Siying, et al.
Publicado: (2019)

Nomogram for Predicting Recurrence-Free Survival in Chinese Women with Endometrial Cancer after Initial Therapy: External Validation
por: Cheng, Yuan, et al.
Publicado: (2020)

Survival Nomogram for Young Breast Cancer Patients Based on the SEER Database and an External Validation Cohort
por: Huang, Xiao, et al.
Publicado: (2022)

Development and Validation of a Nomogram for Predicting Risk of Emergency Department Revisits in Chinese Older Patients
por: Fan, Lijun, et al.
Publicado: (2022)

Development and validation of a nomogram for assessing survival in patients with hepatocellular carcinoma after hepatectomy
por: Huo, Rong-Rui, et al.
Publicado: (2020)

Bioinformatics analysis of key genes in triple negative breast cancer and validation of oncogene PLK1
por: Ren, Yi, et al.
Publicado: (2020)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
por: Liu, Jieqiong, et al.
Publicado: (2020)

Construction and validation of a nomogram for predicting cancer-specific survival in hepatocellular carcinoma patients
por: Liu, Kang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n0kmhcurr7m4tb1vncclmhnoof